123 reports of this reaction
18.6% of all BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE reports
#1 most reported adverse reaction
CEREBROVASCULAR ACCIDENT is the #1 most commonly reported adverse reaction for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, manufactured by Foundation Consumer Brands. There are 123 FDA adverse event reports linking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE to CEREBROVASCULAR ACCIDENT. This represents approximately 18.6% of all 662 adverse event reports for this drug.
Patients taking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE who experience cerebrovascular accident should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CEREBROVASCULAR ACCIDENT is a frequently reported adverse event for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, accounting for a significant proportion of all reports.
In addition to cerebrovascular accident, the following adverse reactions have been reported for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE:
The following drugs have also been linked to cerebrovascular accident in FDA adverse event reports:
CEREBROVASCULAR ACCIDENT has been reported as an adverse event in 123 FDA reports for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CEREBROVASCULAR ACCIDENT accounts for approximately 18.6% of all adverse event reports for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, making it one of the most commonly reported side effect.
If you experience cerebrovascular accident while taking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.